Assignee
SALIX PHARMACEUTICALS INC
US·17 granted patents·31 pending applications·100 citations·filing 1995–2025
Top patents by PatentIndex Score
48 records- 0197US11633384B2Methods of treating hepatic encephalopathySALIX PHARMACEUTICALS INC·Filed 2021·Granted Apr 25, 2023·3 cites·10 claims
- 0296US10709694B2Methods of treating hepatic encephalopathySALIX PHARMACEUTICALS INC·Filed 2019·Granted Jul 14, 2020·6 cites·13 claims
- 0396US7452872B2Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivativesSALIX PHARMACEUTICALS INC·Filed 2007·Granted Nov 18, 2008·39 cites·20 claims
- 0495US11311521B2Solid dispersion forms of rifaximinSALIX PHARMACEUTICALS INC·Filed 2021·Granted Apr 26, 2022·3 cites·6 claims
- 0595US11129817B2Solid dispersion forms of rifaximinSALIX PHARMACEUTICALS INC·Filed 2021·Granted Sep 28, 2021·4 cites·12 claims
- 0694US11660292B2Solid dispersion forms of rifaximinSALIX PHARMACEUTICALS INC·Filed 2021·Granted May 30, 2023·3 cites·2 claims
- 0794US10874647B2Solid dispersion forms of rifaximinSALIX PHARMACEUTICALS INC·Filed 2019·Granted Dec 29, 2020·7 cites·4 claims
- 0890US2024299368A1Methods of treating hepatic encephalopathySALIX PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 0989US2025082616A1Solid Dispersion Forms of RifaximinSALIX PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 1088US2025367175A1Solid Dispersion Forms of RifaximinSALIX PHARMACEUTICALS INC·Filed 2025·Application pending·0 cites
- 1188US2026014126A1Solid Dispersion Forms of RifaximinSALIX PHARMACEUTICALS INC·Filed 2025·Application pending·0 cites
- 1286US9034892B2Forms of rifaximin and uses thereofSALIX PHARMACEUTICALS INC·Filed 2013·Granted May 19, 2015·6 cites·20 claims
- 1386US2024342142A1Methods for treating irritable bowel syndrome (ibs)SALIX PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 1486US2024285591A1Methods for treating irritable bowel syndrome (ibs)SALIX PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 1584US11564912B2Methods for treating irritable bowel syndrome (IBS)SALIX PHARMACEUTICALS INC·Filed 2022·Granted Jan 31, 2023·0 cites·7 claims
- 1684US2024100028A1Solid dispersion forms of rifaximinSALIX PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 1784US2024148704A1Methods for treating irritable bowel syndrome (ibs)SALIX PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 1883US10456384B2Methods for treating irritable bowel syndrome (IBS)SALIX PHARMACEUTICALS INC·Filed 2018·Granted Oct 29, 2019·2 cites·15 claims
- 1976US11779571B2Methods for treating irritable bowel syndrome (IBS)SALIX PHARMACEUTICALS INC·Filed 2021·Granted Oct 10, 2023·0 cites·4 claims
- 2076US2023181571A1Use of methylnaltrexone to attenuate tumor progressionSALIX PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 2174US9725466B2Rifaximin derivative and uses thereofSALIX PHARMACEUTICALS INC·Filed 2016·Granted Aug 8, 2017·1 cites·20 claims
- 2274US2020163958A1Use of methylnaltrexone to attenuate tumor progressionSALIX PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 2374US2020368213A1Methods of treating hepatic encephalopathySALIX PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 2473US2025228828A1Methods of treating hepatic encephalopathySALIX PHARMACEUTICALS INC·Filed 2025·Application pending·0 cites
- 2572US12285414B2Methods of treating hepatic encephalopathySALIX PHARMACEUTICALS INC·Filed 2022·Granted Apr 29, 2025·0 cites·10 claims
- 2671US10765667B2Methods for treating irritable bowel syndrome (IBS)SALIX PHARMACEUTICALS INC·Filed 2020·Granted Sep 8, 2020·0 cites·16 claims
- 2771US2020121653A1Methods for treating irritable bowel syndrome (ibs)SALIX PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 2869US2021121456A1Use of methylnaltrexone to attenuate tumor progressionSALIX PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 2965US2020397904A1Formulations of rifaximin and uses thereofSALIX PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 3064US10328088B2Use of aminosalicylates in diarrhoea-predominent irritable bowel syndromeSALIX PHARMACEUTICALS INC·Filed 2018·Granted Jun 25, 2019·0 cites·12 claims
- 3163US2020101090A1Use of aminosalicylates in diarrhoea-predominent irritable bowel syndromeSALIX PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 3263US2020268790A1Electrolyte purgativeSALIX PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 3361US2020276170A1Methods for retreating irritable bowel syndrome (ibs)SALIX PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 3460US5905073AUse of 2-hydroxy-5-phenylazobenzoic acid derivatives as colon cancer chemopreventative and chemotherapeutic agentsSALIX PHARMACEUTICALS INC·Filed 1995·Granted May 18, 1999·26 cites·9 claims
- 3560US2020230116A1Methods for retreating irritable bowel syndrome (ibs)SALIX PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 3658US2017105977A1Methods for retreating irritable bowel syndrome (ibs)SALIX PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 3757US2016000765A1Methods for treating bowel diseasesSALIX PHARMACEUTICALS INC·Filed 2015·Application pending·0 cites
- 3856US2017202832A1Use of methylnaltrexone to attenuate tumor progressionSALIX PHARMACEUTICALS INC·Filed 2017·Application pending·0 cites
- 3954US2008260682A1Polyethylene glycol colonic purgative compositionSALIX PHARMACEUTICALS INC·Filed 2007·Application pending·0 cites
- 4054US2009252788A1Balsalazide formulations and manufacture and use thereofSALIX PHARMACEUTICALS INC·Filed 2008·Application pending·0 cites
- 4154US2008306029A1Prevention, Treatment, and Amelioration of Radiation Induced EnteritisSALIX PHARMACEUTICALS INC·Filed 2005·Application pending·0 cites
- 4251US2014349983A1Method for treating ulcerative colitisSALIX PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 4347US2019240229A1Gastric and colonic formulations and methods for making and using themSALIX PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 4445US2015216806A1Laxative compositions and methods for treating constipation and related gastrointestinal diseases and conditionsSALIX PHARMACEUTICALS INC·Filed 2013·Application pending·0 cites
- 4543US2015132284A1Method of treating ulcerative colitisSALIX PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 4642US2014349982A1Methods of treating ulcerative colitisSALIX PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 4735US10493064B2IBS microbiota and uses thereofSALIX PHARMACEUTICALS INC·Filed 2016·Granted Dec 3, 2019·0 cites·4 claims
- 4835US2015164868A1Methods of administering rifaximin without producing antibiotic resistanceSALIX PHARMACEUTICALS INC·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when SALIX PHARMACEUTICALS INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →